REGENXBIO Inc. (RGNX) is a biological products, (no diagnostic substances) company, listed on the Nasdaq. With a market capitalization of $468 million, REGENXBIO Inc. is a small-cap company. The stock currently trades at $9.24, up 2.21% today, with a 52-week range of $5.04–$16.19.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-4.59 | $-4.59 | +23.8% | |
| 2023 | $-6.02 | $-6.02 | +7.4% | |
| 2022 | $-6.50 | $-6.50 | -323.4% | |
| 2021 | $2.91 | $3.01 | +334.7% | |
| 2020 | $-1.24 | $-1.24 | -72.2% | |
| 2019 | $-0.72 | $-0.72 | -754.5% | |
| 2018 | $0.11 | $0.12 | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-13 | 0000950170-25-038770 | SEC ↗ |
| 2023-12-31 | 2024-02-27 | 0000950170-24-021161 | SEC ↗ |
| 2022-12-31 | 2023-02-28 | 0000950170-23-005085 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001564590-22-008055 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001564590-21-009855 | SEC ↗ |
| 2019-12-31 | 2020-02-26 | 0001564590-20-006826 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001564590-19-004920 | SEC ↗ |
| 2017-12-31 | 2018-03-06 | 0001564590-18-004532 | SEC ↗ |
| 2016-12-31 | 2017-03-07 | 0001564590-17-003576 | SEC ↗ |
| 2015-12-31 | 2016-03-03 | 0001564590-16-013941 | SEC ↗ |